ArticleMicromachines2019
Endothelial Cell Activation in an Embolic Ischemia-Reperfusion Injury Microfluidic Model.
Article in Micromachines, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Injury-on-a-chip for modelling microvascular trauma-induced coagulation.Lab on a chip · 2025Article
- Engineering Organ-on-a-Chip Systems for Vascular Diseases.Arteriosclerosis, thrombosis, and vascular biology · 2023Review
- Cancer-on-chip: a 3D model for the study of the tumor microenvironment.Journal of biological engineering · 2023Review
- Electroacupuncture reverses endothelial cell death and promotes angiogenesis through the VEGF/Notch signaling pathway after focal cerebral ischemia-reperfusion injury.Brain and behavior · 2023Article
- Novel, Innovative Models to Study Ischemia/Reperfusion-Related Redox Damage in Organ Transplantation.Antioxidants (Basel, Switzerland) · 2022Review
- Microfluidic Model to Evaluate Astrocyte Activation in Penumbral Region following Ischemic Stroke.Cells · 2022Article
- Targeting vascular inflammation through emerging methods and drug carriers.Advanced drug delivery reviews · 2022Review
- Advances in Immunomodulation and Immune Engineering Approaches to Improve Healing of Extremity Wounds.International journal of molecular sciences · 2022Review
- Technology-based approaches toward a better understanding of neuro-coagulation in brain homeostasis.Cell and tissue research · 2022Review
- Galectin-1 alleviates myocardial ischemia-reperfusion injury by reducing the inflammation and apoptosis of cardiomyocytes.Experimental and therapeutic medicine · 2022Article
- Recent Advances in Cardiac Tissue Engineering for the Management of Myocardium Infarction.Cells · 2021Review
- Tackling Ischemic Reperfusion Injury With the Aid of Stem Cells and Tissue Engineering.Frontiers in physiology · 2021Review
- Development and Testing of Thrombolytics in Stroke.Journal of stroke · 2021Review
- Editorial for the Special Issue on Organs-on-Chips.Micromachines · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Ischemia, lack of blood supply, is associated with a variety of life-threatening cardiovascular diseases, including acute ischemic stroke and myocardial infraction. While blood flow restoration is critical to prevent further damage, paradoxically, rapid reperfusion can increase tissue damage. A variety of animal models have been developed to investigate ischemia/reperfusion injury (IRI), however they do not fully recapitulate human physiology of IRI. Here, we present a microfluidic IRI model utilizing a vascular compartment comprising human endothelial cells, which can be obstructed via a human blood clot and then re-perfused via thrombolytic treatment. Using our model, a significant increase in the expression of the endothelial cell inflammatory surface receptors E-selectin and I-CAM1 was observed in response to embolic occlusion. Following the demonstration of clot lysis and reperfusion via treatment using a thrombolytic agent, a significant decrease in the number of adherent endothelial cells and an increase in I-CAM1 levels compared to embolic occluded models, where reperfusion was not established, was observed. Altogether, the presented model can be applied to allow better understanding of human embolic based IRI and potentially serve as a platform for the development of improved and new therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.